A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Spinosad (Natroba)

Pediculicide class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2011-01-25
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$930,240 in CY2024 Part D spend3K claims · 3K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.93/unit
5 NDCs benchmarked, lowest of all strengths.
Average NADAC
$2.04
Across all dosage forms in distribution.
Highest NADAC
$2.20
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Spinosad used for?

Spinosad is a Pediculicide medication tracked in Medicare Part D.

Is there a generic for Spinosad?

No. Spinosad is brand-only with no generic equivalents currently in market.

How much does my plan pay for Spinosad?

Across 329 Part D plans, Spinosad averages $2.04/unit (NADAC). Lowest available: $1.93/unit. Highest in distribution: $2.20/unit.

Is Spinosad on the FDA shortage list?

No. Spinosad is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.